MYGN Short Information, Myriad Genetics Inc.

Twenty Trading Day Totals
Total Shorted Volume	1,919,753
Total Actual Volume	20,976,727

Averages
Average Short Volume	95,988
Average Short Percentage	52.77%

Is there a MYGN Short Squeeze or Breakout about to happen?

See the MYGN Short Analysis for free Sign up or Login

Stock Date	Open Price	Close Price	High	Low	Total Volume	Short Volume	Short Percentage
2020-05-22	14.72	14.73	14.81	14.09	553,365	80,351	60.0302
2020-05-21	14.59	14.69	15.04	14.53	510,327	55,965	68.4947
2020-05-20	14.8236	14.61	15.18	14.467	865,976	64,092	66.8795
2020-05-19	14.97	14.49	15.09	14.48	613,506	49,391	68.1161
2020-05-18	15.41	15	15.55	14.79	817,416	78,102	61.4938
2020-05-15	14.21	14.73	14.88	14.1714	717,205	99,273	63.1363
2020-05-14	14.7	14.28	14.85	13.84	815,184	70,272	55.6967
2020-05-13	14.27	14.98	15	14	1,044,745	121,574	60.7989
2020-05-12	16.11	14.37	16.13	14.27	1,135,748	155,613	73.0728
2020-05-11	15.23	15.92	16.06	14.895	2,250,846	175,191	18.8956
2020-05-08	15.16	14.62	15.16	13.94	1,245,651	86,990	24.1986
2020-05-07	14.41	14.91	15.24	14.27	1,179,877	86,213	32.0503
2020-05-06	13.51	14.23	14.6315	13.28	1,472,748	114,420	34.5122
2020-05-05	15.67	14.82	15.82	14.41	1,685,640	209,699	44.3808
2020-05-04	14.74	15.25	15.3	14.41	1,298,829	135,329	51.3567
2020-05-01	15.14	14.8	15.44	14.36	899,275	78,486	55.6737
2020-04-30	15.48	15.46	15.96	15.12	1,146,798	44,772	46.9387
2020-04-29	15.32	15.73	15.96	14.7152	1,178,495	48,534	39.9710
2020-04-28	15.83	14.82	15.83	14.76	629,460	77,932	63.2817
2020-04-27	14.69	15.35	15.53	14.44	915,636	87,554	66.3891

Stock Information

Myriad Genetics Inc. Company Name:

MYGN Stock Symbol:

NASDAQ Market:

Myriad Genetics Inc. Website:

MYGN Short Information, Myriad Genetics Inc.

Get MYGN Alerts

News, Short Squeeze, Breakout and More Instantly...

RECENT MYGN NEWS

MYGN - FDA OKs two companion diagnostics for Lynparza for prostate cancer

The FDA approves Myriad Genetics' (NASDAQ: MYGN ) BRACAnalysis CDx test and Roche ( OTCQX:RHHBY ) unit Foundation Medicine's FoundationOne CDx test for use as a companion diagnostics to identify suitable metastatic castration-resistant prostate cancer (mCRPC) pat...
MYGN - Myriad Receives FDA Approval of BRACAnalysis CDx® as a Companion Diagnostic for Lynparza® in HRR-mutated Metastatic Castration-Resistant Prostate Cancer

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx ® test for use as a compani...
MYGN - Could Exact Sciences Be a Millionaire-Maker Stock?

Cancer diagnostic leader Exact Sciences (NASDAQ: EXAS) isn't having the best of years, and not just because of the COVID-19 pandemic. In February, the company announced it was selling approximately $1 billion in senior convertible notes to raise money. These notes will carry an annual i...